Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 6/20 | 0.51 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.49 |
| ▸ | TK1 | P04183 | 5/20 | 0.47 |
| ▸ | TK2 | O00142 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7620908 | 1.00 | TOP2A (0.51) | TOP2ARNASE1TK1TK2 | |
| SCHEMBL7922852 | 1.00 | TOP2A (0.51) | TOP2ARNASE1TK1TK2 | |
| SCHEMBL8610578 | 1.00 | TOP2A (0.51) | TOP2ARNASE1TK1TK2 | |
| SCHEMBL7621283 | 0.91 | TOP2A (0.49) | TOP2ARNASE1TK1TK2 | |
| SCHEMBL7917918 | 0.89 | RNASE1 (0.51) | TOP2ARNASE1TK1TK2 | |
| SCHEMBL5802542 | 0.88 | POLB (0.55) | TOP2ATK1 | |
| SCHEMBL5802545 | 0.88 | POLB (0.55) | TOP2ATK1 | |
| SCHEMBL8188889 | 0.87 | TK1 (0.62) | TOP2ARNASE1TK1TK2 | |
| SCHEMBL8185778 | 0.87 | TOP2A (0.58) | TOP2ARNASE1TK1TK2 | |
| SCHEMBL7623504 | 0.87 | TK1 (0.62) | TOP2ARNASE1TK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6214551-B1 | CONTACTING TEST SOLUTION CONTAINING NUCLEIC ACID WITH COMPOUND CONTAINING NUCLEOSIDE SEQUENCE WHEREIN NUCLEOSIDES ARE COVALENTLY BOUND THROUGH LINKING GROUP HAVING ADJACENT NITROGEN ATOMS FOR ASSAYING SEQUENCE-SPECIFIC NUCLEIC ACID | ISIS PHARMACEUTICALS, INC. | 2001-04-10 | — | — | US | disclosed |
| US-6025482-A | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5808023-A | Modified oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5792844-A | MIMIC AND/OR MODULATE THE ACTIVITY OF WILD-TYPE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5489677-A | NUCLEASE RESISTANT OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-06 | — | — | US | disclosed |
| US-5386023-A | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling | ISIS PHARMACEUTICALS (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1994022883-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDES AND THEIR PREPARATION | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022893-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022454-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT OXYGEN AND NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |